Digital Platform: AI-Powered HTA Reporting
Automated health-economic evidence generation β compressing market assessments that once took weeks and cost hundreds of thousands into a matter of hours, and delivering internationally standard evidence packages for reimbursement negotiation.
Four core functions
AI Drug Screening Engine
A three-tier evidence system (pharmacopoeia evidence, policy guidance, literature evidence) with AI auto-grading and scoring to efficiently pinpoint target products.
Global Market Screening
233-country funnel analysis: compliance screening β patient pool β out-of-pocket affordability β competitive landscape β five-dimension weighted scoring, locating high-value markets.
CEA Model Building
Automated cost-effectiveness analysis (CEA) modelling with real-time ICER estimation, aligned with each country's HTA review requirements (AMCP / NICE / local formats).
Value Dossier Generation
Clinical plus health-economic evidence packaged in one click to produce standardized AMCP / NICE submission documents for formulary listing and reimbursement negotiation.
233 countries β 57 priority markets
A reproducible screening funnel that turns "which country first" from a gut decision into a structured one.
Five-dimension weighted score
| Dimension | Weight |
|---|---|
| Disease burden | 25% |
| Competitive gap | 20% |
| Reimbursement access | 25% |
| Registration speed | 20% |
| Payer capacity | 10% |
Country-selection criteria: single payer (concentrated decision-making) Β· short HTA review timelines Β· largest Chinese price advantage Β· reach into regional market blocs.
Three-tier evidence system
The platform automatically grades and scores evidence across three tiers β pharmacopoeia, policy guidance and literature β building a credible evidence foundation.
π Pharmacopoeia evidence
Covers inclusion in the Chinese Pharmacopoeia and leading international pharmacopoeias (USP, EP, BP), plus listing status in the WHO Essential Medicines List.
ποΈ Policy & guidance
Tracks NICE technology appraisals, FDA/EMA approval status, WHO essential medicines and recommendation grades in national clinical guidelines.
π¬ Literature evidence
Aggregates systematic reviews / meta-analyses, RCTs, real-world studies and health-economic analyses, outputting evidence grades (Level Ia β β β β β ).
How the three evidence tiers produce a "gradeable" conclusion
Using a type-2 diabetes candidate as an example, the platform automatically aggregates the three evidence tiers and issues a composite score and evidence grade β the "evidence foundation" for entering national HTA review and reimbursement negotiation.
| Evidence tier | Example conclusion | What the platform summarises |
|---|---|---|
| π Pharmacopoeia evidence | Included in national pharmacopoeias Β· listed in WHO EML | Listed in the Chinese Pharmacopoeia and leading international pharmacopoeias (USP, EP, BP); included in the WHO Essential Medicines List / Model List. |
| ποΈ Policy & guidance | Regulatory approval Β· guideline recommendation | FDA/EMA approval status, NICE technology appraisal opinions, and first-line recommendation grades in international guidelines such as ADA/EASD. |
| π¬ Literature evidence | Level Ia β β β β β | Aggregates systematic reviews / meta-analyses, RCTs, real-world and health-economic studies, outputting an evidence grade and total evidence volume. |
Output format: automatically generates A+ / composite scores (e.g. 95/100) and evidence grading, and in one click produces CEA reports aligned with each country's HTA review plus AMCP / NICE-format Value Dossiers β completing the journey from "evidence" to "submittable documentation" in a single step.
The platform is developed in-house by Qiyang. For software licensing, partnership options and demo bookings, please contact us for a commercial proposal.
Want to see the platform run your product?
Book an online demo and we will walk a real product through the full journey from 233-country screening to report generation.
Book a demo